SynthesisFrontiers in medicine2025
Immune regulation and clinical response of Chinese herbal injections combined with TACE in hepatocellular carcinoma: a cumulative logit regression and Bayesian network meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study evaluated the immunomodulatory effects and clinical efficacy of Chinese herbal injections (CHIs) combined with transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients using cumulative logit regression and Bayesian network meta-analysis. Methods: A systematic review of 48 randomized controlled trials (RCTs) involving 4,293 HCC patients was conducted using PubMed, Cochrane Library, EMBASE, Scopus, and Google Scholar. Outcomes included immune markers (CD3+, CD4+, CD8+, CD4+/CD8+ ratio, and NK cells), clinical response rate, and overall survival (6-month, 1-year, and 2-year). Cumulative logit regression and Bayesian network meta-analysis were applied to synthesize ordinal and continuous outcomes. Results: Compared to TACE alone, Aidi, Compound Kushen, and Huachansu significantly enhanced the immune function. Aidi increased CD3+ T cells (MD = 10.95, 95% CI: 8.04-13.86), CD4+ T cells (MD = 7.13, 4.37-9.89), CD4+/CD8+ ratio (MD = 0.31, 0.20-0.41), and NK cells (MD = 6.30, 4.49-8.12), while Compound Kushen showed the highest CD4+/CD8+ improvement (MD = 0.47, 0.37-0.56) and NK cell elevation (MD = 9.11, 7.32-10.91). Huachansu increased CD3+ T cells (MD = 8.74, 4.43-13.06) and CD4+ T cells (MD = 8.00, 4.21-11.80). For clinical outcomes, Compound Kushen (HR = 2.57, 1.9-3.59) and Aidi (HR = 2.28, 1.68-3.18) improved clinical response rates versus TACE. Aidi enhanced 6-month (OR = 2.57, 1.44-4.56) and 1-year survival (OR = 2.46, 1.56-3.88), whereas Huachansu (OR = 3.47, 2.42-4.97) and Compound Kushen (OR = 2.91, 1.07-7.89) improved 2-year survival. Conclusion: Aidi, Compound Kushen, and Huachansu enhance immune function and survival in HCC patients when combined with TACE. Compound Kushen showed the most significant immunomodulatory effects, while Aidi and Huachansu improved short- and long-term survival, respectively. Further high-quality head-to-head RCTs are required to validate these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.